Champions Oncology Stock News

Champions Oncology's (CSBR) CEO Ronnie Morris on Q3 2022 Results - Earnings Call Transcript

HACKENSACK, NJ / ACCESSWIRE / March 11, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-ph

Jounce Therapeutics, Inc. (JNCE) delivered earnings and revenue surprises of -156.52% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the

Champions Oncology <> is collaborating with GigaMune for next generation T cell therapies and cancer diagnostics.The partnership will combine Champions'' novel autologous…

Champions Oncology <> is collaborating with Fannin Innovation Studio to develop next generation therapeutics drug conjugates for tumors.The partnership will combine novel

Champions Oncology Inc (CSBR) shares closed today at 1.7% above its 52 week low of $7.75, giving the company a market cap of $106M. The stock is currently down 5.7% year-to-date, down 27.9% over the past 12 months, and up 144.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 1.9%. Trading Activity Trading volume this week was 61.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -45.1% The company's stock price performance over the past 12 months lags the peer average by -320.5% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Champions Oncology Inc (CSBR) shares closed today at 1.7% above its 52 week low of $7.75, giving the company a market cap of $106M. The stock is currently down 5.7% year-to-date, down 29.3% over the past 12 months, and up 144.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 61.7% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 3.6% lower than its 5-day moving average, 2.5% lower than its 20-day moving average, and 16.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -41.8% The company's stock price performance over the past 12 months lags the peer average by -306.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Champions Oncology Inc (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, stock rose 3.23% (As The post Champions Oncology Inc (NASDAQ:CSBR) is debt free appeared first on FXDailyReport.Com .

Champions Oncology, Inc. (NASDAQ: CSBR) Q2 2022 earnings call dated Dec. 13, 2021. Corporate Participants: Ronnie Morris — President & Chief Executive Officer David Miller — Chief Financial Officer Analysts: Matt Hewitt — Craig-Hallum — Analyst […] The post Champions Oncology, Inc. (CSBR) Q2 2022 Earnings Call Transcript first appeared on AlphaStreet .

Reported income from operations of $263,000HACKENSACK, NJ / ACCESSWIRE / December 13, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming…

Champions Oncology Inc.'s (CSBR) CEO Ronnie Morris on Q2 2022 Results - Earnings Call Transcript